Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
Author:
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
http://link.springer.com/content/pdf/10.1186/s40661-015-0020-3.pdf
Reference67 articles.
1. National Cancer Institute: SEER Stat Fact Sheets: Endometrial Cancer. http://seer.cancer.gov/statfacts/html/corp.html . Accessed August 23 2015.
2. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159–66. doi: 10.1200/JCO.2004.07.184 .
3. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65. doi: 10.1200/JCO.2010.32.6397 .
4. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(3):538–43. doi: 10.1016/j.ygyno.2012.08.020 .
5. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(1):22–7. doi: 10.1016/j.ygyno.2012.12.022 .
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CCL22 as an independent prognostic factor in endometrial cancer patients;Translational Oncology;2024-12
2. Uncovering a novel DNA repair-related radiosensitivity model for evaluation of radiotherapy susceptibility in uterine corpus endometrial cancer;Heliyon;2024-04
3. The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review;Life;2023-07-03
4. Current Methods and Advances in the Immunotherapy Treatment of Non-Ovarian Gynaecological Cancers;Future Pharmacology;2023-06-01
5. Immunotherapy in Gynaecological Oncology: The Italian Landscape;Clinical and Experimental Obstetrics & Gynecology;2023-05-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3